Last updated on April 2018

Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease


Brief description of study

MESENCHYMAL STROMAL CELLS (MSC) have shown promising albeit not always consistent therapeutic effects in the treatment of severe steroid-resistant acute Graf versus Host Disease. Remarkably, in all reported clinical studies the toxicity of Mesenchymal stromal cells administration has been found consistently negligible. The investigators believe that Umbilical Cord (UC) derived Mesenchymal stromal cells may represent a stronger immunosuppressive tool for such clinical emergency and no data suggest any change in the safety profile of these cells. For this reason, and in the best interest of the patient, the investigators plan to test the safety and activity of Umbilical Cord Mesenchymal stromal cells when given sequentially to another partially effective treatment of steroid resistant acute graf versus host disease such as Pentostatin.

Clinical Study Identifier: NCT02032446

Contact Investigators or Research Sites near you

Start Over

Maria Luisa Ferrari, Study coordinator

A O Papa Giovanni XXIII
Bergamo, Italy
  Connect »

NICOLA MORANDINI, MD

Ao S Croce E Carle
Cuneo, Italy
  Connect »

Riccardo Saccardi, MD

AO Careggi
Firenze, Italy
  Connect »

Edoardo Lanino, MD

IRCCS G Gaslini
Genova, Italy
  Connect »

ALESSANDRO RAMBALDI, MD

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milano, Italy
  Connect »

ALESSANDRO RAMBALDI, MD

Clinica Pediatrica San Gerardo
Monza, Italy
  Connect »

RENATO FANIN, MD

Azienda Ospedaliero-Universitaria Di Udine
Udine, Italy
  Connect »

ALESSANDRO RAMBALDI, MD

Ospedale San Bortolo
Vicenza, Italy
  Connect »